Pueraria mirifica and placebo significantly increased triglyceride levels by 15% from baseline levels (P<0.05).

There were no significant differences in adverse effects on breast tissue, complete blood count, and liver and renal function tests between the Pueraria mirifica and placebo groups in this study.

There were no significant differences in adverse effects on breast tissue, complete blood count, and liver and renal function tests between the Pueraria mirifica and placebo groups in this study.

No endometrial proliferation or hyperplasia was reported after 24 weeks of treatment in both groups.

Endometrial thickness did not change after treatment in both groups (P>0.05).

There were no significant differences in adverse effects on breast tissue, complete blood count, and liver and renal function tests between the Pueraria mirifica and placebo groups in this study.

There were no significant differences in adverse effects on breast tissue, complete blood count, and liver and renal function tests between the Pueraria mirifica and placebo groups in this study.

Mild adverse effects occurred after Pueraria mirifica and placebo treatment.